Design of Intelligent PID Controller for AVR System Using an Adaptive Neuro Fuzzy Inference System

This paper presents a hybrid approach involving signal to noise ratio (SNR) and particle swarm optimization (PSO) for design the optimal and intelligent proportional-integral-derivative (PID) controller of an automatic voltage regulator (AVR) system with uses an adaptive neuro fuzzy inference system (ANFIS). In this paper determined optimal parameters of PID controller with SNR-PSO approach for some events and use these optimal parameters of PID controller for design the intelligent PID controller for AVR system with ANFIS.  Trial and error method can be used to find a suitable design of anfis based an intelligent controller. However, there are many options including fuzzy rules, Membership Functions (MFs) and scaling factors to achieve a desired performance. An optimization algorithm facilitates this process and finds an optimal design to provide a desired performance. This paper presents a novel application of the SNRPSO approach to design an intelligent controller for AVR. SNR-PSO is a method that combines the features of PSO and SNR in order to improve the optimize operation. In order to emphasize the advantages of the proposed SNR-PSO PID controller, we also compared with the CRPSO PID controller. The proposed method was indeed more efficient and robust in improving the step response of an AVR system and numerical simulations are provided to verify the effectiveness and feasibility of PID controller of AVR based on SNRPSO algorithm.DOI:http://dx.doi.org/10.11591/ijece.v4i5.652

Ivermectin: An Effective Remedy Against Various Diseases: A Literature Review

Introduction: Ivermectin is a member of avermectins family which was discovered in 1967in Japan. The contribution of this drug to animal and human health was so prominent thatthe researchers who found the drug were awarded a Noble prize in 2015. With the advent ofCOVID-19,lot of interest has shifted more towards ivermectin usage in treating the COVID-19alone or in combination with other medicines as synergism. Since its introduction, ivermectinhas helped to control many parasitic diseases of animals and humans. For many years after itsdiscovery, ivermectin was considered to be only a parasitic agent, but as scientists continue toevaluate this drug, they discover more healing aspects.Materials and Methods: For this review, we searched keywords from international databasesincluding PubMed, Google Scholar, Science Direct and Scopus. The keywords were ivermectin,anticancer, anti-inflammation, antibacterial, antivirus, antiparasitic, and mechanism of action.Results: Several studies have shown that ivermectin has a very powerful antiparasitic,antibacterial, and antiviral activity and it can also be used as an anticancer and anti-inflammatoryagent.Conclusion: The collected data showed that ivermectin can be used to control and preventmany pathogenic agents and it can also be repurposed for the treatment of COVID-19

Higher order curvature information and its application in a modified diagonal Secant method

A secant equation (quasi-Newton) has one of the most important rule to find an optimal solution in nonlinear optimization. Curvature information must satisfy the usual secant equation to ensure positive definiteness of the Hessian approximation. In this work, we present a new diagonal updating to improve the Hessian approximation with a modifying weak secant equation for the diagonal quasi-Newton (DQN) method. The gradient and function evaluation are utilized to obtain a new weak secant equation and achieve a higher order accuracy in curvature information in the proposed method. Modified DQN methods based on the modified weak secant equation are globally convergent. Extended numerical results indicate the advantages of modified DQN methods over the usual ones and some classical conjugate gradient methods

Effect of Organic and Chemical Fertilizers on Oil Content and other Agronomic Traits of Safflower (Carthamus tinctorios)

The effect of organic fertilizers, chemical nitrogen and phosphorus on oil content and some of agronomic traits of safflower (Carthamus tinctorius), was studied in 2014. A factorial arrangement of treatments in a randomized complete block design with three replications was used. Animal manure treatments (M1= Control, M2= 20 ton.ha-1, M3= 40 ton.ha-1), and Chemical fertilizer treatments (F1= Control, F2= 50 kg.ha-1 of nitrogen + 25 kg.ha-1 of P2O5, F3= 100 kg.ha-1 of nitrogen + 50 kg.ha-1 of P2O5, F4= 150 kg.ha-1 of nitrogen + 75 kg.ha-1 of P2O5) were assigned in plots. In this study characteristics such as: stem diameter, number of sub branch, number of kernels per m-2, biological yield, phosphorus agronomic efficiency, grain weight of capitol, phosphorus physiological efficiency, oil content, nitrogen content of grain, number of unfertile capitol, phosphorus appear recovery and capitol diameter were assessed. Results indicated that the interaction effects of chemical fertilizer and animal manure on the characteristics such as: number of sub branch, biological yield, and nitrogen content of grain, phosphorus agronomic efficiency, phosphorus physiological efficiency and phosphorus appear recovery was significant. The maximum and minimum of phosphorus physiological efficiency (65.88 and 6.21 kg.kg-1) were obtained in  treatment of 50 kg.ha-1 of nitrogen + 25 kg.ha-1 of P2O5 + 40 ton.ha-1 of animal manure and 50 kg.ha-1 of nitrogen + 25 kg.ha-1 of P2O5 + 20 ton.ha-1 of animal manure, respectively

Description of Epidemiological Features, Symptoms and Mortality of the Patients with COVID-19 in Some Provinces of Iran

Background: Clinical manifestations of COVID-19 are different. There are some risk factors for COVID-19. This study aimed to describe the epidemiological features, symptoms and mortality of the patients with COVID-19 in Iran. Methods: This were a cohort study performed on 103,179 patients with COVID-19. The demographic and clinical data were collected in selected provinces. The required data of all patients was extracted from the COVID registry system and analyzed using STATA version 14 and Excel 2016. Results: The mean age was 52.40 years for men and 52.41 years for women. About 55.2% of the study population were male and 44.8% were female. Totally, 60.9% (5085) of deaths happened in men and 39.1% (3263) in women. The mean time from onset of symptoms to hospitalization in men and women were 3.47 and 3.48 days, respectively. The mean time from onset of symptoms to isolation was 2.81 days in men and was 2.87 days in women, from onset of symptoms to death was 9.29 and 9.54 days, respectively, from onset of symptoms to discharge was 7.47 and 7.39 days, and from hospitalization to death was 6.76 and 7.05 days. Cough and shortness of breath were the most common symptoms in the patients. Conclusion: According to the results, the overall mortality rate was higher in men than women. Women with cardiovascular disease and diabetes were more likely to die. The mean time from onset of symptoms to hospitalization, isolation, and discharge was similar in men and women

Current Advances in Internet of Underground Things

The latest developments in Internet of Underground Things are covered in this chapter. First, the IOUT Architecture is discussed followed by the explanation of the challenges being faced in this paradigm. Moreover, a comprehensive coverage of the different IOUT components is presented that includes communications, sensing, and system integration with the cloud. An in-depth coverage of the applications of the IOUT in various disciplines is also surveyed. These applications include areas such as decision agriculture, pipeline monitoring, border control, and oil wells

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.Peer reviewe

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks

Global variations in diabetes mellitus based on fasting glucose and haemogloblin A1c

Fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) are both used to diagnose diabetes, but may identify different people as having diabetes. We used data from 117 population-based studies and quantified, in different world regions, the prevalence of diagnosed diabetes, and whether those who were previously undiagnosed and detected as having diabetes in survey screening had elevated FPG, HbA1c, or both. We developed prediction equations for estimating the probability that a person without previously diagnosed diabetes, and at a specific level of FPG, had elevated HbA1c, and vice versa. The age-standardised proportion of diabetes that was previously undiagnosed, and detected in survey screening, ranged from 30% in the high-income western region to 66% in south Asia. Among those with screen-detected diabetes with either test, the agestandardised proportion who had elevated levels of both FPG and HbA1c was 29-39% across regions; the remainder had discordant elevation of FPG or HbA1c. In most low- and middle-income regions, isolated elevated HbA1c more common than isolated elevated FPG. In these regions, the use of FPG alone may delay diabetes diagnosis and underestimate diabetes prevalence. Our prediction equations help allocate finite resources for measuring HbA1c to reduce the global gap in diabetes diagnosis and surveillance.peer-reviewe

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO